Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Anti FGF23 antibody and a pharmaceutical composition comprising the same
US9290569B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9290569-B2 |
| Application number | US-201113019557-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 2, 2011 |
| Priority date | Feb 14, 2007 |
| Publication date | Mar 22, 2016 |
| Grant date | Mar 22, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).
First claim
Opening claim text (preview).
What is claimed is: 1. An antibody or functional fragment thereof that binds to FGF23, wherein the antibody or functional fragment comprises a heavy and light chain, said heavy chain comprises CDR1 shown by SEQ ID NO: 40, CDR2 shown by SEQ ID NO: 41, and CDR3 shown by SEQ ID NO: 42, and said light chain comprises CDR1 shown by SEQ ID NO: 43, CDR2 shown by SEQ ID NO: 44, and CDR3 shown by SEQ ID NO: 45.
Assignees
Inventors
Classifications
of the parathyroid hormones · CPC title
Drugs for disorders of the endocrine system · CPC title
Antineoplastic agents · CPC title
Nutrients, e.g. vitamins, minerals · CPC title
for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9290569B2 cover?
- To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).
- Who is the assignee on this patent?
- Yamazaki Yuji, Urakawa Itaru, Yoshida Hitoshi, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/244. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).